Yahoo Finance

Morgan Stanley initiated coverage of CSL (CSLLY) with an Overweight rating and A$313 price target A “solid revenue growth outlook” and margin recovery for CSL Behring underpin group EPS growth of about 13% per year over the next three years, the analyst tells investors.

Light Up your Portfolio with Spark:

• Easily identify stocks' risks and opportunities.

• Discover stocks' market position with detailed competitor analyses.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CSLLY:

Questions or Comments about the article? Write to editor@tipranks.com

• Arcturus Therapeutics and CSL’s Kostaive COVID-19 vaccine approved in Europe

• CSL, Arcturus Therapeutics announce European Commission approval for Kostaive

• CSL Limited Earnings Call Highlights Growth and Challenges

• CSL Limited Reports Strong Half-Year Financial Performance